Clinical Trial Update: Treatment of B-CLL With Autologous IL2 and CD40 Ligand-Expressing Tumor Cells + Lenalidomide [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating a combination of autologous IL-2, CD40 ligand-expressing tumor cells, and lenalidomide for B-cell chronic lymphocytic leukemia has been…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia

Drugs mentioned

• CD40 Ligand-Expressing Tumor Cells
• Interleukin-2 (interleukin-2)
• Lenalidomide (lenalidomide)

Snippet

Sponsor: Baylor College of Medicine | Conditions: B-cell Chronic Lymphocytic Leukemia | Phase 1 | Status: TERMINATED